抄録
The unpredictability and uncertainty of the COVID-19 pandemic; the associated lockdowns, physical distancing, and other containment strategies; and the resulting economic breakdown could increase the risk of mental health problems and exacerbate health inequalities. Preliminary findings suggest adverse mental health effects in previously healthy people and especially in people with pre-existing mental health disorders. Despite the heterogeneity of worldwide health systems, efforts have been made to adapt the delivery of mental health care to the demands of COVID-19. Mental health concerns have been addressed via the public mental health response and by adapting mental health services, mostly focusing on infection control, modifying access to diagnosis and treatment, ensuring continuity of care for mental health service users, and paying attention to new cases of mental ill health and populations at high risk of mental health problems. Sustainable adaptations of delivery systems for mental health care should be developed by experts, clinicians, and service users, and should be specifically designed to mitigate disparities in health-care provision. Thorough and continuous assessment of health and service-use outcomes in mental health clinical practice will be crucial for defining which practices should be further developed and which discontinued. For this Position Paper, an international group of clinicians, mental health experts, and users of mental health services has come together to reflect on the challenges for mental health that COVID-19 poses. The interconnectedness of the world made society vulnerable to this infection, but it also provides the infrastructure to address previous system failings by disseminating good practices that can result in sustained, efficient, and equitable delivery of mental health-care delivery. Thus, the COVID-19 pandemic could be an opportunity to improve mental health services.
本文言語 | English |
---|---|
ページ(範囲) | 813-824 |
ページ数 | 12 |
ジャーナル | The Lancet Psychiatry |
巻 | 7 |
号 | 9 |
DOI | |
出版ステータス | Published - 2020 9月 |
ASJC Scopus subject areas
- 精神医学および精神衛生
- 生物学的精神医学
UN SDG
この成果は、次の持続可能な開発目標に貢献しています
文献へのアクセス
他のファイルとリンク
フィンガープリント
「How mental health care should change as a consequence of the COVID-19 pandemic」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。引用スタイル
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
How mental health care should change as a consequence of the COVID-19 pandemic. / Moreno, Carmen; Wykes, Til; Galderisi, Silvana その他.
In: The Lancet Psychiatry, Vol. 7, No. 9, 09.2020, p. 813-824.研究成果: Review article › 査読
}
TY - JOUR
T1 - How mental health care should change as a consequence of the COVID-19 pandemic
AU - Moreno, Carmen
AU - Wykes, Til
AU - Galderisi, Silvana
AU - Nordentoft, Merete
AU - Crossley, Nicolas
AU - Jones, Nev
AU - Cannon, Mary
AU - Correll, Christoph U.
AU - Byrne, Louise
AU - Carr, Sarah
AU - Chen, Eric Y.H.
AU - Gorwood, Philip
AU - Johnson, Sonia
AU - Kärkkäinen, Hilkka
AU - Krystal, John H.
AU - Lee, Jimmy
AU - Lieberman, Jeffrey
AU - López-Jaramillo, Carlos
AU - Männikkö, Miia
AU - Phillips, Michael R.
AU - Uchida, Hiroyuki
AU - Vieta, Eduard
AU - Vita, Antonio
AU - Arango, Celso
N1 - Funding Information: CM and CA are co-financed by the European Regional Development Fund; have received support from the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI17/02227, and PI19/024), the European Commission; CIBERSAM, the Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), Fundación Familia Alonso, Fundación Alicia Koplowitz, and Fundación Mutua Madrileña; and have received European Union Structural Funds via the European Union Seventh Framework (FP7-4-HEALTH-2009-2.2.1-2-241909, FP7-HEALTH-2013-2.2.1-2-603196, and FP7-HEALTH-2013-2.2.1-2-602478) and the European Union H2020 programme under the Innovative Medicines Initiative 2 Joint Undertaking (115916 and 777394). TW acknowledges support from the National Institute for Health Research Maudsley Biomedical Research Centre at the South London and Maudsley NHS Foundation Trust and King's College London (IS-BRC-1215-20018) and the National Institute for Health Research Senior Investigator Award (NF-SI-0514-10028). MRP acknowledges support from the National Natural Science Foundation of China (81371502 and 81761128031). EV acknowledges the support of the Spanish Ministry of Science and Innovation (PI15/00283 and PI18/00805), funding that was integrated into the Plan Nacional de I+D+I and co-financed by the ISCIII—Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional; the Instituto de Salud Carlos III; CIBERSAM; the Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement (2017 SGR 1365); the CERCA Programme; and the Departament de Salut de la Generalitat de Catalunya (PERIS grant SLT006/17/00357). MC is supported by a European Research Council Consolidator Award (iHear 724809). We acknowledge Giulia Maria Giordano (University of Campania “Luigi Vanvitelli”, Naples, Italy) and Pasquale Pezzella (University of Campania “Luigi Vanvitelli”, Naples, Italy). Funding Information: CM reports personal fees from Janssen, Angelini, Servier, Nuvelution, Otsuka, and Lundbeck. SG reports personal fees from Lundbeck, Janssen, Sunovion, Gedeon Richter-Recordati, and Angelini; and has consulted or served on advisory boards for Millennium Pharmaceuticals, Innova Pharma-Recordati Group, Janssen, Gedeon Richter-Recordati, and Angelini; and non-financial support from Gedeon Richter-Recordati. CUC has been a consultant or advisor for Alkermes, Allergan, Angelini, Boehringer-Ingelheim, Gedeon Richter-Recordati, Gerson Lehrman, Indivior, IntraCellular Therapies, Janssen, Johnson & Johnson, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Merck, Neurocrine, Noven, Otsuka, Pfizer, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva; has received honoraria from Angelini, Gedeon Richter-Recordati, IntraCellular Therapies, Janssen, Johnson & Johnson, Lundbeck, Otsuka, Pfizer, Sumitomo Dainippon, and Sunovion; provided expert testimony for Janssen and Otsuka; served on data safety monitoring boards for Lundbeck, Rovi, Supernus, and Teva; received grant support from Janssen and Takeda; and holds stock options in LB Pharma. PG received fees for presentations at congresses or participation in scientific boards from Alcediag-Alcen, Angelini, GlaxoSmithKline, Janssen, Lundbeck, Otsuka, SAGE, and Servier. EYHC reports grants from Janssen and Otsuka; personal fees and non-financial support from Janssen, Otsuka, and DSK BioPharma; and received support for a psychoeducation programme from Janssen and DSK BioPharma. JHK reports personal fees from AstraZeneca, Biogen, Biomedisyn, Bionomics, Boehringer Ingelheim, COMPASS Pathways, Concert, Epiodyne, EpiVario, Heptares, Janssen Research & Development, Perception Neuroscience, Spring Care, Sunovion, Takeda, Taisho, Bioasis, Biohaven, BioXcel, BlackThorn Therapeutics, Cadent Therapeutics, Cerevel Therapeutics, Lohocla, Novartis, PsychoGenics, and Biological Psychiatry; holds stock in Biohaven, Sage, and Spring Care; holds stock options in Biohaven, BlackThorn Therapeutics, EpiVario, and Terran Life Sciences; has served as a consultant for Otsuka; and has served on science advisory boards for Terran Life Sciences. Additionally, JHK holds patents related to the treatment of mental disorders (US patent numbers 5 447 948 and 8 778 979 B2; US application numbers 14/197 767, 14/197.767; provisional use patent application number 61/973/961; and US Patent and Trademark Office docket number Y0087.70116US00), and two other patents are pending (US provisional patent application numbers 62/444 552 and 62/719 935). JL has received grants and non-financial support from Alkermes, Boehringer Ingelheim, Lilly/DeNovo, Teva, and Taisho, non-financial support from Alkermes, Boehringer Ingelheim, IntraCellular Therapies, Karuna, Lilly/DeNovo, Pierre Fabre, Teva, and Taisho, and medication supplies for investigator-initiated research from Lilly/DeNovo; has served as an advisory board member for IntraCellular Therapies, Karuna, and Pierre Fabre; and has a patent to Repligen issued. HU reports grants and personal fees from Eisai, Otsuka, Sumitomo Dainippon, and Meiji-Seika. EV reports personal fees from Abbott, Allergan, Angelini, Janssen, Lundbeck, Sage, and Sanofi, and grants from Sumitomo Dainippon, Ferrer, and Janssen. AV reports personal fees from Angelini, Innovapharma, Janssen-Cilag, Lundbeck, Otsuka, and Recordati, and grants from Boehringer Ingelheim, Janssen-Cilag, Lundbeck, Otsuka, and Takeda. CA reports personal fees from Acadia, Angelini, Gedeon Richter, Janssen Cilag, Lundbeck, Minerva, Otsuka, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon, Sunovion, and Takeda. All other authors declare no competing interests. Funding Information: CM and CA are co-financed by the European Regional Development Fund; have received support from the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI17/02227, and PI19/024), the European Commission; CIBERSAM, the Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), Fundación Familia Alonso, Fundación Alicia Koplowitz, and Fundación Mutua Madrileña; and have received European Union Structural Funds via the European Union Seventh Framework (FP7-4-HEALTH-2009-2.2.1-2-241909, FP7-HEALTH-2013-2.2.1-2-603196, and FP7-HEALTH-2013-2.2.1-2-602478) and the European Union H2020 programme under the Innovative Medicines Initiative 2 Joint Undertaking (115916 and 777394). TW acknowledges support from the National Institute for Health Research Maudsley Biomedical Research Centre at the South London and Maudsley NHS Foundation Trust and King's College London (IS-BRC-1215-20018) and the National Institute for Health Research Senior Investigator Award (NF-SI-0514-10028). MRP acknowledges support from the National Natural Science Foundation of China (81371502 and 81761128031). EV acknowledges the support of the Spanish Ministry of Science and Innovation (PI15/00283 and PI18/00805), funding that was integrated into the Plan Nacional de I+D+I and co-financed by the ISCIII—Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional; the Instituto de Salud Carlos III; CIBERSAM; the Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement (2017 SGR 1365); the CERCA Programme; and the Departament de Salut de la Generalitat de Catalunya (PERIS grant SLT006/17/00357). MC is supported by a European Research Council Consolidator Award (iHear 724809). We acknowledge Giulia Maria Giordano (University of Campania “Luigi Vanvitelli”, Naples, Italy) and Pasquale Pezzella (University of Campania “Luigi Vanvitelli”, Naples, Italy). Publisher Copyright: © 2020 Elsevier Ltd
PY - 2020/9
Y1 - 2020/9
N2 - The unpredictability and uncertainty of the COVID-19 pandemic; the associated lockdowns, physical distancing, and other containment strategies; and the resulting economic breakdown could increase the risk of mental health problems and exacerbate health inequalities. Preliminary findings suggest adverse mental health effects in previously healthy people and especially in people with pre-existing mental health disorders. Despite the heterogeneity of worldwide health systems, efforts have been made to adapt the delivery of mental health care to the demands of COVID-19. Mental health concerns have been addressed via the public mental health response and by adapting mental health services, mostly focusing on infection control, modifying access to diagnosis and treatment, ensuring continuity of care for mental health service users, and paying attention to new cases of mental ill health and populations at high risk of mental health problems. Sustainable adaptations of delivery systems for mental health care should be developed by experts, clinicians, and service users, and should be specifically designed to mitigate disparities in health-care provision. Thorough and continuous assessment of health and service-use outcomes in mental health clinical practice will be crucial for defining which practices should be further developed and which discontinued. For this Position Paper, an international group of clinicians, mental health experts, and users of mental health services has come together to reflect on the challenges for mental health that COVID-19 poses. The interconnectedness of the world made society vulnerable to this infection, but it also provides the infrastructure to address previous system failings by disseminating good practices that can result in sustained, efficient, and equitable delivery of mental health-care delivery. Thus, the COVID-19 pandemic could be an opportunity to improve mental health services.
AB - The unpredictability and uncertainty of the COVID-19 pandemic; the associated lockdowns, physical distancing, and other containment strategies; and the resulting economic breakdown could increase the risk of mental health problems and exacerbate health inequalities. Preliminary findings suggest adverse mental health effects in previously healthy people and especially in people with pre-existing mental health disorders. Despite the heterogeneity of worldwide health systems, efforts have been made to adapt the delivery of mental health care to the demands of COVID-19. Mental health concerns have been addressed via the public mental health response and by adapting mental health services, mostly focusing on infection control, modifying access to diagnosis and treatment, ensuring continuity of care for mental health service users, and paying attention to new cases of mental ill health and populations at high risk of mental health problems. Sustainable adaptations of delivery systems for mental health care should be developed by experts, clinicians, and service users, and should be specifically designed to mitigate disparities in health-care provision. Thorough and continuous assessment of health and service-use outcomes in mental health clinical practice will be crucial for defining which practices should be further developed and which discontinued. For this Position Paper, an international group of clinicians, mental health experts, and users of mental health services has come together to reflect on the challenges for mental health that COVID-19 poses. The interconnectedness of the world made society vulnerable to this infection, but it also provides the infrastructure to address previous system failings by disseminating good practices that can result in sustained, efficient, and equitable delivery of mental health-care delivery. Thus, the COVID-19 pandemic could be an opportunity to improve mental health services.
UR - http://www.scopus.com/inward/record.url?scp=85089296136&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089296136&partnerID=8YFLogxK
U2 - 10.1016/S2215-0366(20)30307-2
DO - 10.1016/S2215-0366(20)30307-2
M3 - Review article
C2 - 32682460
AN - SCOPUS:85089296136
VL - 7
SP - 813
EP - 824
JO - The Lancet Psychiatry
JF - The Lancet Psychiatry
SN - 2215-0366
IS - 9
ER -